BACKGROUND: The current standard of care for salvage treatment of @entity463 ( @entity463 ) is gross total resection and adjuvant chemoradiation for operable @entity1 . Limited evidence exists to suggest that any particular treatment modality improves survival for recurrent @entity463 , especially if inoperable. We report our experience with fractionated stereotactic radiotherapy (fSRT) with and without chemo/immunotherapy, identifying prognostic factors associated with prolonged survival. METHODS: From 2007 to 2014, 19 @entity1 between 29 and 78   years old (median 55) with recurrent @entity463 following resection and chemoradiation for their initial @entity5 , received 18-35   Gy (median 25) in three to five fractions via CyberKnife fSRT. Clinical target volume (CTV) ranged from 0.9 to 152   cc. Sixteen @entity1 received adjuvant systemic therapy with bevacizumab ( @entity1493 ), @entity2903 ( @entity2904 ), anti-epidermal growth factor receptor (125)I-mAb 425, or some combination thereof. RESULTS: The median @entity1349 ( @entity1349 ) from date of recurrence was 8   months (2.5-61) and 5.3   months (0.6-58) from the end of fSRT. The @entity1349 at 6 and 12   months was 47 and 32%, respectively. Three of 19 @entity1 were alive at the time of this review at 20, 49, and 58   months from completion of fSRT. Hazard ratios for survival indicated that @entity1 with @entity1313 , adjuvant treatment with either @entity1493 or @entity2904 , time to first recurrence >16   months, CTV <36   cc, recursive partitioning analysis <5, and Eastern Cooperative Oncology Group performance status <2 were all associated with improved survival (P   <   0.05). There was no evidence of radionecrosis for any @entity1 . CONCLUSION: Radiation Therapy Oncology Group (RTOG) 1205 will establish the role of re-irradiation for recurrent @entity463 , however our study suggests that CyberKnife with chemotherapy can be safely delivered, and is most effective in @entity1 with @entity1313 , good performance status, or long interval from diagnosis.

Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent XXXX : A Single Institution Experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1313 :: ('MESH:D001932', 'Disease') :: ['a frontal lobe tumor', 'smaller frontal lobe tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity2904 :: ('CHEBI:72564', 'Chemical') :: ['TMZ'] @entity1493 :: ('12064', 'Species') :: ['BEV'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity463 :: (MESH:D005909,Disease) :: ['Glioblastoma Multiforme']
